ISRCTN11133689进行中（未招募）未知
Randomised open-label controlled feasibility trial of probiotic in the elimination of faecal carriage carbapenemase-bearing Klebsiella pneumoniae
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Written informed consent
- •2. Male or female; aged 18 years or older
- •3. Immunocompetent as per medical history
- •4. TCD-KP detected on rectal screening in the last 2 months
- •5. Not currently hospital inpatient (when planning starting probiotic supplementation)
- •All individuals will be considered for inclusion in this study regardless of age, disability, gender reassignment, marriage and civil partnership, pregnancy and maternity, race, religion and belief, sex, and sexual orientation except where the study inclusion and exclusion criteria EXPLICITLY state otherwise.
排除标准
- •1. Any active infection at the time of enrolment
- •2. Presence of or likely to develop mucositis on examination, as per medical history
- •3. History of Presence cardiac prostheses
- •4. Consumption of any marketed probiotic product in the 30 day period prior to enrolment and during the duration of the trial
- •5. Consumption of Over the Counter (OTC) medication or herbal remedies labelled as to improve your immunity system or for daily immunity”
- •6. In receipt of systemic or intestinal antibiotic within 14 days before baseline samples to be taken
- •7. Receiving or intended to receive antibiotic within 30 days of 1st baseline sample
- •8. Current and past history of pancreatitis
- •9. Concurrent melaena
- •10. Abdominal surgery within the 3 months prior to study enrolment
- •11. Known pericardial constriction, genetic hypertrophic cardiomyopathy, or infiltrative cardiomyopathy
- •12. Any medical condition, which in the opinion of the Investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study
- •13. Past medical history of Severe renal dysfunction at Visit 0, defined as e GFR <30 mL/min, or end-stage renal disease requiring dialysis.
- •14. History of severe hepatic impairment or liver dysfunction at Visit 0, defined as total bilirubin above the ULN (excluding patients with Gilbert’s syndrome), AST or ALT >3 times the ULN or alkaline phosphatase >2.5 times the ULN
- •15. Known hypersensitivity to any of the components of the probiotic.
- •16. Pregnancy, lactation or planning pregnancy. A pregnancy test will not be required before study enrolment, however, if a woman determines that she is pregnant during the study period, she must stop the probiotic
研究者
相似试验
已完成
2 期
An open label Randomized Controlled Clinical trial to Evaluate the Safety and Efficacy of selected Siddha formulations in patients diagnosed with COVID-19CTRI/2020/06/025768ational Institute of Siddha215
尚未招募
Unknown
A study on the effect of intermittent fasting in reducing the blood sugar level and number of medicines in type 2 diabetic patients.CTRI/2023/09/057784Jawaharlal Nehru Medical College
尚未招募
4 期
To study the effect of use of prophylactic Glycerin enema versus Glycerin suppository versus no intervention on time required to reach full feeds in very low birth weight neonatesCTRI/2024/07/070434Bharati Vidyapeeth Deemed University Medical College Pune
尚未招募
3 期
A research study to compare one variety of oral lipid supplement called SQLNS with oral Iron and folic acid (IFA) syrup for improvement in blood hemoglobin levels among children aged 6 months to 2 years, by providing the supplements daily for 3 months duratioCTRI/2023/12/060854Aravind M
进行中（未招募）
1 期
Can giving medication up the nose and through the lining of the mouth control symptoms as effectively as injections for people approaching the end of life? – Pilot StudyEUCTR2013-005009-30-GBGloucestershire Hospitals NHS Foundation Trust and20